title: Antithrombotic therapy for ischaemic stroke patients with AF/RHD in West China daily practice.
abstract: OBJECTIVE
  Although, current evidence-based guidelines advocate anticoagulation as a strong recommendation in IS patients with AF/RHD, the underuse of anticoagulation in IS patients with AF/RHD has been found in clinical practice worldwide. Nevertheless, there was little information about implementation of antithrombotic therapy to prevent stroke for patients with AF and/or RHD in daily practice in West China. Our study determined to clarify the patterns, adherence and comparative effect of antithrombotic treatment during 1-year follow-up in IS patients with AF and/or RHD.
  
  
  METHODS
  Consecutive patients with acute IS and AF/RHD admitted to Department of Neurology, West China Hospital from November 2010 to October 2011 were included in the study.
  
  
  RESULTS
  155 consecutive patients were analysed in this study. One hundred thirteen patients have been diagnosed as AF and/or RHD before admission. Of these, 49 (43.4%) patients were receiving antithrombotic therapy before the time of admission, including nine (8.0%) patients receiving warfarin. At 12  months after stroke onset, 109 (81.3%) patients were on antithrombotics, and 46 (34.3%) patients were on warfarin alone. The persistence rate of warfarin use at 1 year was 77.8%. Moreover, there were 80 (81.6%) patients never starting to use warfarin. Compared with no antithrombotic therapy, anti-platelets and warfarin reduced death risk significantly during 1-year after stroke onset (P = 0.005).
  
  
  CONCLUSIONS
  Our study suggests that overall real-world use of warfarin in IS patients with AF and/or RHD is low before and after admission in West China. Implementation study on this respect should be conducted in this area to improve the daily practice.
authors.forename: Deren
authors.initials: D
authors.lastname: Wang
authors.forename: Junfeng
authors.initials: J
authors.lastname: Liu
authors.forename: Zilong
authors.initials: Z
authors.lastname: Hao
authors.forename: Ming
authors.initials: M
authors.lastname: Liu
authors.forename: Ge
authors.initials: G
authors.lastname: Tan
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Jiang
authors.forename: Wendan
authors.initials: W
authors.lastname: Tao
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy*; D002681:China; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin
keywords: Antithrombotic therapy,; Atrial fibrillation,; Comparative research; Ischaemic stroke,; Rheumatic heart disease,